Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...

The global hepatitis B diagnostic tests market is on the brink of significant expansion, driven by a surge in disease incidence, heightened awareness campaigns, and rapid advancements in diagnostic ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

Hepatitis B affects almost 300 million people worldwide, according to GSK, and while NAs to treat it are available – such as Gilead’s polymerase inhibitor Viread (tenofovir) – there is still ...

drugs to treat it are available – such as Gilead’s polymerase inhibitor Viread (tenofovir) – there is still no curative treatment. A functional cure is said to have been achieved if HBsAg is ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Most of the antiviral agents that have been approved, and are currently used in the treatment of virus infections, are targeted at HIV, HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV ...

Drug-resistance amino acids known in HIV-1 [36] are shown in bold. Amino acids that are the same as those of the reference HIV-1 HXB2 are shown as bars. † Consensus amino acid sequences were ...

After hours: October 10 at 7:42 PM EDT Loading Chart for GILD ...

After hours: 7 October at 19:32 GMT-4 ...